$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
患者服用瑞博西林一个周期的费用
2025-10-19 11:44:20
Check Details
瑞博西利在绝经前HR阳性晚期乳腺癌一线治疗中有着巨大潜力
2025-10-19 11:44:20
Check Details
晚期乳腺癌服用瑞博西林进行治疗的效果
2025-10-19 11:44:20
Check Details
CDK4/6抑制剂瑞博西林多少钱一盒?国内能买到吗?
2025-10-19 11:44:20
Check Details
CDK4/6抑制剂瑞博西利给乳腺癌晚期带来了哪些好处?
2025-10-19 11:44:20
Check Details
瑞博西林是治疗HR+/HER2-绝经后晚期乳腺癌的口服抗癌靶向药
2025-10-19 11:44:20
Check Details
CDK4/6抑制剂瑞博西利治疗乳腺癌晚期的效果显著
2025-10-19 11:44:20
Check Details
奥拉帕利治疗HER2阴性转移性乳腺癌的安全性和耐受性
2025-10-19 11:44:20
Check Details
瑞博西林可有效提高HR+/HER2-绝经前晚期乳腺癌患者生存期
2025-10-19 11:44:20
Check Details
乳腺癌患者服用爱博新进行治疗能活多久?
2025-10-19 11:44:20
Check Details
奥拉帕利可以用于治疗三阴性乳腺癌患者吗?
2025-10-19 11:44:20
Check Details
瑞博西林的出现,使绝经前晚期乳腺癌患者获益
2025-10-19 11:44:20
Check Details
1
2
...
2000
2001
2002
2003
2004
2005
2006
...
4159
4160
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Sotorasib (Lumakras): A Comprehensive Guide to the First KRAS G12C-Targeted Inhibitor
2
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
3
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
4
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
5
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
6
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment
7
Lapatinib: A Targeted Anticancer Agent — Not Merely Symptom Relief
8
Lapatinib: Proper Administration Guide and Key Precautions
9
Capivasertib (Truqap) Complete Medication Guide: Indications, Dosing, Safety, and Precautions
10
Cemiplimab Storage and Handling Guide
11
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
12
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring